Physician profile
Robert I Fish
NPI 1285707034
$11,559.00
in general payments reported to CMS, 2019-2025
23 companies · $593 in 2025
The $593 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $3,520 · 2021: $2,488 · 2022: $2,894 · 2023: $245 · 2024: $1,099 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337 · Honoraria: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.91 |
| Honoraria | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $8,395.91 | 2019-2022 | |
| Harrow Eye, LLC | $711.10 | 2024 | Vevye |
| Alcon Vision LLC | $621.93 | 2022-2025 | Clareon, Hydrus Microstent |
| Sight Sciences, INC. | $524.47 | 2020-2025 | Omni Surgical System, Tearcare System, Sion Surgical Instrument |
| Abbvie INC. | $205.25 | 2022-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $156.90 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $130.81 | 2025 | Acthar |
| Aerie Pharmaceuticals, INC. | $106.27 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $85.64 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $71.22 | 2019-2024 | |
| New World Medical,INC. | $60.70 | 2025 | Kahook Dual Blade, Via360, Clearpath |
| Rxsight INC | $59.66 | 2021-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Kowa Pharmaceuticals America, INC. | $58.85 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $56.31 | 2021-2024 | Tecnis Simplicity, Tecnis Iol |
| Kala Pharmaceuticals, INC. | $55.64 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $49.08 | 2019 | |
| Dompe US, INC. | $44.56 | 2019-2024 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $40.71 | 2019 | |
| Glaukos Corporation | $38.03 | 2020-2022 | |
| Biotissue Holdings INC. | $33.49 | 2022 | |
| Ocular Therapeutix, INC. | $20.80 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.46 | 2022 | |
| Katena Products, INC. (Dba Corza Medical) | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.